Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-08-21 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
第四届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of several proposals including the 2024 semi-annual report, equity distribution plan, and a special report on the use of raised funds. The document references the actual reports being disclosed separately on the Beijing Stock Exchange information platform with specific announcement numbers. The text itself does not contain the full semi-annual report or detailed financial data but rather announces the resolutions passed in the Supervisory Board meeting. The document length is short (1549 characters) and it primarily serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution disclosure, not as the actual interim report or financial report.
2024-08-21 Chinese
权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement of a 2024 semi-annual dividend distribution plan by Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes specifics on the dividend amount, the basis for distribution, board and supervisory committee approvals, independent director opinions, and references to company articles of association regarding profit distribution. It also mentions the need for shareholder meeting approval and the timing of dividend payments. The document is not a full financial report but an announcement of a dividend plan and related corporate governance details. It is not a simple notice of dividend amount but a comprehensive dividend distribution proposal and plan. Therefore, it fits best under the category of Notice of Dividend Amount (DIV). The document length is under 5,000 characters, but it contains substantive content about the dividend plan, not just a brief announcement or a link to a report, so it is not an RPA or RNS filing.
2024-08-21 Chinese
关于完成工商变更登记及公司章程备案并取得营业执照的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the completion of industrial and commercial registration changes and the filing of the company's articles of association, including obtaining a new business license. It references prior announcements about proposed changes to registered capital and company bylaws but does not contain detailed financial statements or performance data. The document is short (779 characters) and serves as a formal notification of completed corporate registration and capital change procedures. This fits the category of Share Issue/Capital Change (SHA) because it involves changes in registered capital and related filings, rather than a full financial report or other types of filings.
2024-08-12 Chinese
投资者关系活动记录表
Investor Presentation Classification · 90% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record." It details a specific investor relations event held on August 8, 2024, including participants, questions asked, and company responses. The content focuses on company products, market strategy, and future plans, typical of an investor relations meeting or presentation. The document length is short (1567 characters), and it does not contain financial statements or detailed financial data. It is not an earnings release or annual/interim report. It is not a regulatory filing or certification. The document is a record of an investor relations activity, which aligns best with the category of Investor Presentation (IP).
2024-08-11 Chinese
董事长、监事会主席、高级管理人员换届公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election and appointment of the company's chairman, supervisory board chairman, and senior management personnel. It details the changes in board and senior management positions, their qualifications, and the impact of these changes on the company. There are no financial statements or financial performance data included. The document is focused on management changes rather than financial results or reports. Therefore, it fits the category of Board/Management Information (MANG). The document length is 2557 characters, which is consistent with a detailed announcement rather than a full report.
2024-08-01 Chinese
使用闲置自有资金购买理财产品公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the use of idle own funds to purchase wealth management products. It details the purpose, amount, method, duration, decision-making process, risk analysis, and impact on the company. The document is relatively short (1379 characters) and does not contain financial statements or detailed financial data. It is a disclosure about a financing-related activity (use of funds for investment in financial products) but not a full capital or financing update report. It is an announcement of a financing-related decision approved by the board, describing the intended use of funds and risk controls. This fits best under Capital/Financing Update (CAP) as it relates to the company's capital management and financing activities, specifically the use of idle funds for investment. It is not a full financial report, audit, or regulatory filing, nor is it a voting result or management change. Therefore, the classification is CAP with high confidence.
2024-08-01 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.